Abstract: Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.

Abstract: Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.

Abstract: Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.

Abstract: Disclosed are a novel Bifidobacterium longum RAPO (Accession No.: KCTC 13773BP) and a composition for alleviating, treating or preventing rheumatoid arthritis containing Bifidobacterium longum RAPO (Accession No.: KCTC 13773BP) selected herein.

Abstract: Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.

Abstract: Provided is a prebiotic composition containing butyryl-fructooligosaccharide (B-FOS). B-FOS of the present invention facilitates selective growth of probiotics, thereby controlling intestinal microbes and contributing to physiological functions as an energy source of intestinal epithelial cells.

Abstract: Disclosed are a novel Bifidobacterium longum RAPO (Accession No.: KCTC 13773BP) and a composition for alleviating, treating or preventing rheumatoid arthritis containing Bifidobacterium longum RAPO (Accession No.: KCTC 13773BP) selected herein.

Abstract: Provided is a composition containing Bifidobacterium for alleviating, preventing or treating rheumatoid arthritis. The Bifidobacterium bifidum ATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.

Abstract: Provided is a prebiotic composition containing butyryl-fructooligosaccharide (B-FOS). B-FOS of the present invention facilitates selective growth of probiotics, thereby controlling intestinal microbes and contributing to physiological functions as an energy source of intestinal epithelial cells.

Abstract: Provided is a composition containing Bifidobacterium for alleviating, preventing or treating rheumatoid arthritis. The Bifidobacterium bifidum ATT newly isolated according to the present invention is useful as a rheumatoid arthritis medicine or a probiotic material for alleviating rheumatoid arthritis owing to potent efficacy in treating rheumatoid arthritis.

Abstract: The present invention relates to a new plasmid originated from (Bifidobacterium) a recombinant expression vector and transformation method using the same. More particularly, the present invention relates to a plasmid pMG1 having nucleotide sequence represented by SEQ.ID.NO.1; (Bifidobacterium longum) MG1 including the plasmid pMG1; and a shuttle vector which can be replicated in both (Bifidobacterium) and (E. coli), and comprises (Mob) gene having nucleotide sequence represented by SEQ.ID.NO.2. (Rep) gene having nucleotide sequence represented by SEQ.ID.NO.3 and a selection marker. The shuttle vector and the promoter of the present invention can be used for expressing target gene without additional purification process.

Abstract: The present invention relates to a new plasmid originated from (Bifidobacterium) a recombinant expression vector and transformation method using the same. More particularly, the present invention relates to a plasmid pMG1 having nucleotide sequence represented by SEQ.ID.NO. 1; (Bifidobacterium longum) MG1 including the plasmid pMG1; and a shuttle vector which can be replicated in both (Bifidobacterium) and (E. coli), and comprises (Mob) gene having nucleotide sequence represented by SEQ.ID.NO. 2. (Rep) gene having nucleotide sequence represented by SEQ.ID.NO. 3 and a selection marker. The shuttle vector and the promoter of the present invention can be used for expressing target gene without additional purification process. The protein expressed from the target gene in (Bifidobacterium) can be added to food, therefore, the protein can be used for preparing food additives or oral vaccine.